Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

22004

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Postpartum Hypertension
Interventions: Remote Medical Model (RMM), Community Health Model (CHM), SoC; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: New Haven, Connecticut • Worcester, Massachusetts • Buffalo, New York

Conditions: Hypoxic-Ischemic Encephalopathy
Interventions: RLS-0071, Placebo; Drug
Lead sponsor: ReAlta Life Sciences, Inc.; Industry
Eligibility: Up to 10 Hours
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 22
States / cities: Little Rock, Arkansas • Orange, California • San Diego, California + 17 more

Conditions: Metabolic Disease, Propionic Acidemia, Organic Acidemia
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 1 Month to 100 Years
Enrollment: 1,045 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2036
U.S. locations: 2
States / cities: Bethesda, Maryland • Pittsburgh, Pennsylvania

Conditions: Diabetic Macular Edema (DME)
Interventions: 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 57
States / cities: Scottsdale, Arizona • Encino, California • Fullerton, California + 50 more

Conditions: Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Urea Cycle Disorders, Inborn
Interventions: No Intervention; Other
Lead sponsor: iECURE, Inc.; Industry
Eligibility: 7 Months to 15 Months
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2041
U.S. locations: 2
States / cities: Aurora, Colorado • New York, New York

Conditions: Disruptive Behavior Disorders, Conduct Disorder, Oppositional Defiant Disorder, Attention-deficit/Hyperactivity Disorder
Interventions: Psychotherapy; Behavioral
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 8 Years to 13 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Allergic Conjunctivitis
Interventions: REGN-2Cat, Freneslerbart, Mevonlerbart, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 8 Years and older
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Long Beach, California • Andover, Massachusetts

Conditions: Amblyopia
Interventions: Amblyopia Therapy, 1 mg Psilocybin, 5 mg Psilocybin, 10 mg Psilocybin, 15 mg Psilocybin, 20 mg Psilocybin, 25 mg Psilocybin; Behavioral · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Interventions: Divarasib, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 69
States / cities: Anchorage, Alaska • Goodyear, Arizona • Clovis, California + 66 more

Conditions: Advanced Malignancies, Advanced Cancer
Interventions: PF-07994525, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 27
States / cities: Denver, Colorado • New Haven, Connecticut • North Haven, Connecticut + 11 more

Conditions: Myasthenia Gravis
Interventions: Nipocalimab, Placebo, Nipocalimab SC-LIV; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 24
States / cities: Paradise Valley, Arizona • Scottsdale, Arizona • Los Angeles, California + 21 more

Conditions: Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Triple Negative Breast Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
Interventions: NKT3964, Paclitaxel, Doxorubicin; Drug
Lead sponsor: NiKang Therapeutics, Inc.; Industry
Eligibility: 19 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 19
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more

Recruiting clinical trials

Filter and sort this status page

Live official records

Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic Acidemia

A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)

Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool

A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy

Psilocybin for Amblyopia - Targeting Critical Periods in Humans

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors